Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network

Carfilzomib is a Food and Drug Administration-approved selective proteasome inhibitor for patients with multiple myeloma (MM). However, recent studies indicate that MM cells still develop resistance to carfilzomib, and the molecular mechanisms associated with carfilzomib resistance have not been stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhihong, Liu, Tingbo, Zheng, Jing, Hu, Jianda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338971/
https://www.ncbi.nlm.nih.gov/pubmed/28280367
http://dx.doi.org/10.2147/OTT.S130742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338971/
https://www.ncbi.nlm.nih.gov/pubmed/28280367
http://dx.doi.org/10.2147/OTT.S130742

Ejemplares similares